Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing
Advertisement

Related Content

Beijing FDA Gives Quick Nod For H7N9 Rapid Testing Agent
Merck Unveils $1.5 Billion Expansion In China With New Beijing R&D Center; Plans To Double R&D Team By 2014
China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Merck Invests In China Oncology Start-up BeiGene
Advertisement
UsernamePublicRestriction

Register

SC078730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel